Four Emerging Companies That Are On Everyone’s Radar, Today June 16

Jun 16, 2016, 12:00 ET from FN Media Group, LLC

MIAMI, June 16, 2016 /PRNewswire/ -- Briefing:  The overall markets traded lower Thursday morning as oil slid in price.  Energy traded more than 1.5% lower as the biggest loser in the S&P 500, followed by financials. U.S. crude oil futures traded more than 2.5% lower to under $47 a barrel. But in light of this, other stocks have traded higher during Thursday's morning session on momentum and above average volume.  Four stocks that are being traded heavily before 11AM EST have been given a full breakdown below:

Gevo, Inc. (NASDAQ: GEVO) announced today that it has entered into an agreement with Musket Corporation to supply isobutanol for blending with gasoline.  Isobutabol has been used in marine gasoline applications because of the superior properties of isobutanol-blended gasolines, it can prevent moisture absorption and phase separation.  It has also be shown to reduce engine corrosion; provide higher energy content; and contain a high octane rating. GEVO's supply program is expected to begin with railcar quantities of isobutanol. One railcar can hold roughly 29,000 gallons.  

Since falling from highs of over $1 last week, GEVO shares have begun to rebound this week.  Thursday's morning highs of $0.667 marked a rebound of more than 50% since Monday's (6/13) opening bell.

LifeClips Inc. (OTC: LCLP) (OTCQB: LCLP) has been making several key announcements this month including the announcement that the company has solidified the acquisition agreement to buy Batterfly Energy, the makers of Mobeego.  The company also announced on Wednesday (6/15) that it has officially begun the presale process of its SoloVu 4K action camera on the company's website. "This has been an exciting month for LifeClips. It is with great pleasure and pride that we begin our pre-sale for SoloVu™. If it seems that we are being aggressive in our development as a company, we are! It is my goal and the goal of the entire (LCLP) team to ensure the growth & success of LifeClips and to continue to provide outstanding shareholder value," said Bob Gruder CEO LifeClips, Inc.

Since early May, shares of LCLP have seen a climb from $0.25 to highs of $0.76 and after having pulled back to lows of $0.45 last week, the stock has seen a rebound by as much as 43%.  The stock has also begun to see higher lows over the last 4 days of trading.

Medovex Corp. (NASDAQ: MDVX) has also seen a very strong month of June.  Since June 2 when MDVX was trading around $1.50 the market has been reacting bullish with regard to the overall sentiment in the market.  This was proven but the increase in price and volume that the stock has seen since then.  Just a few days ago MDVX traded as high as $2.48 and was up more than 60% since early June.  The company is in the midst of testing its DenerveX™ System, which has successfully been used in its most extensive live tissue test to date. Last week the company announced that it completed an extensive twelve subject live tissue laboratory using the most stringent standards for Good Laboratory Practice standards (GLP) using the final pre-production model device and generator.  On Thursday, the stock has slightly recovered from a two-day sell-off period since hitting those $2.48 highs.  It should also be noted that MDVX has not seen trading levels like this in nearly 9 months.

Oxis International (OTC: OXIS) (OTCQB: OXIS) has begun to see an increase in trading activity during the month of June.  From trading an average of roughly 70-80 thousand shares per day in months prior, OXIS has seen that average increase to roughly 120,000 shares traded per day in June.  This may have been due to the increase in attention that the biotech sector as a whole has been given as of late.  Oxis specifically has focused on cancer treatments including multiple myeloma and triple negative breast cancer.  The company's lead drug candidate, OXS-1550, is a novel bispecific scFv recombinant fusion protein-drug conjugate that the company believes to be a powerful alternative to existing chemotherapies.  This is since many patients fail chemotherapy or reach the toxic limits of their therapy.

DISCLAIMER:  FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with or any company mentioned herein.  The commentary, views and opinions expressed in this release by are solely those of and are not shared by and do not reflect in any manner the views or opinions of FNM.  The companies that are discussed herein may or may not have approved the statements made in this release.  FNM is not liable for any investment decisions by its readers or subscribers FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM was not compensated by any public company mentioned herein to disseminate this press release.


This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information: Company:  FN Media Group, LLC Contact e-mail: U.S. Phone: +1(954)345-0611


SOURCE FN Media Group, LLC